Admission to Trading Application
Oxford Biomedica PLC has applied to the London Stock Exchange for the admission to trading of 7,363 ordinary shares of 50 pence each, which have been allotted under the OXB Deferred Bonus Plan and the OXB Sharesave Scheme. These new ordinary shares are expected to be admitted to trading on 14 August 2026 and will rank equally with existing shares.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 11 August 2026: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that application has been made to the London Stock Exchange for the admission to trading of 7,363 ordinary shares of 50 pence each in the Company (the "New Ordinary Shares").
The requested admission relates to ordinary shares which have been alloted under:
- OXB Deferred Bonus Plan (DBP)
- OXB Sharesave Scheme (SAYE)
It is expected that admission becomes effective on 14 August 2026. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.